Solara Active Pharma Sciences Ltd Stock Price Today (NSE: SOLARA)
Fundamental Score
Solara Active Pharma Sciences Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Solara Active Pharma Sciences Ltd share price today is ₹483.70, up +0.00% on NSE/BSE as of 17 February 2026. Solara Active Pharma Sciences Ltd (SOLARA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.32K (Cr). The 52-week high for SOLARA share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 361.52x, SOLARA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 0.05% and a debt-to-equity ratio of 0.51.
Solara Active Pharma Sciences Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Solara Active Pharma Sciences Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Solara Active Pharma Sciences Share Price: A Conservative Value Investor's Perspective
The pharmaceutical industry, while offering immense growth potential, demands stringent regulatory compliance and significant R&D investment. This creates a complex landscape where consistent profitability is paramount. This analysis examines the current standing of Solara Active Pharma Sciences share price (₹470.850006) through the lens of a conservative value investor, prioritizing capital safety and long-term sustainability.
At first glance, Solara's current Price-to-Earnings (PE) ratio of 361.52 raises concerns. A high PE ratio often indicates that the market has high growth expectations baked into the price. However, for a value investor, such a premium necessitates exceptional underlying performance and a robust margin of safety, which appears absent currently. Compared to its peers like
Mankind Pharma Ltd, where assessments suggest a more experienced and perhaps better-regarded management team, Solara's leadership track record warrants close scrutiny regarding consistent execution and capital allocation.A critical metric for evaluating a company's efficiency is its Return on Capital Employed (ROCE). Solara's ROCE of 6.01% is particularly noteworthy. A low ROCE suggests that the company is not efficiently deploying capital to generate profits. This directly impacts the strength of its "moat," or competitive advantage. A company with a higher ROCE is typically better positioned to reinvest earnings, innovate, and defend its market share. Solara's current ROCE, however, indicates a vulnerability, potentially making it more susceptible to competition and economic downturns.
Ultimately, a conservative value investor would exercise caution. While Solara Active Pharma Sciences Ltd. operates in a vital sector, the elevated PE ratio coupled with the relatively low ROCE signals a need for further investigation and a cautious approach. Before any investment consideration, a deeper dive into the company's financial statements, future growth prospects, and competitive landscape is essential. This analysis forms part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra and focuses solely on observed data, offering no buy or sell recommendations.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Solara Active Pharma Sciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SOLARA across key market metrics for learning purposes.
Positive Indicators
0 factors identified
No significant strengths identified in current analysis.
Risk Factors
12 factors identified
Below-Average Return on Equity (0.05%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.01%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 361.52x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-226.09%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-9.63%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-0.58% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-65.82% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-65.77% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (1.06x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-178.22 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
High Share Pledging Risk (35.32%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Solara Active Pharma Sciences Ltd Financial Statements
Comprehensive financial data for Solara Active Pharma Sciences Ltd including income statement, balance sheet and cash flow
About SOLARA (Solara Active Pharma Sciences Ltd)
Solara Active Pharma Sciences Ltd (SOLARA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹2.32K (Cr). Solara Active Pharma Sciences Ltd has delivered a Return on Equity (ROE) of 0.05% and a ROCE of 6.01%. The debt-to-equity ratio stands at 0.51, reflecting the company's capital structure. Investors tracking SOLARA share price can monitor key metrics including P/E ratio, promoter holding of 42.01%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
SOLARA Share Price: Frequently Asked Questions
What is the current share price of Solara Active Pharma Sciences Ltd (SOLARA)?
As of 17 Feb 2026, 10:22 am IST, Solara Active Pharma Sciences Ltd share price is ₹483.70. The SOLARA stock has a market capitalisation of ₹2.32K (Cr) on NSE/BSE.
Is SOLARA share price Overvalued or Undervalued?
SOLARA share price is currently trading at a P/E ratio of 361.52x, compared to the industry average of 31.77x. Based on this relative valuation, the Solara Active Pharma Sciences Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SOLARA share price?
The 52-week high of SOLARA share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Solara Active Pharma Sciences Ltd share price?
Key factors influencing SOLARA share price include quarterly earnings growth (Sales Growth: -9.63%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Solara Active Pharma Sciences Ltd a good stock for long-term investment?
Solara Active Pharma Sciences Ltd shows a 5-year Profit Growth of -65.77% and an ROE of 0.05%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.51 before investing in SOLARA shares.
How does Solara Active Pharma Sciences Ltd compare with its industry peers?
Solara Active Pharma Sciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare SOLARA share price P/E of 361.52x and ROE of 0.05% against the industry averages to determine competitive standing.
What is the P/E ratio of SOLARA and what does it mean?
SOLARA share price has a P/E ratio of 361.52x compared to the industry average of 31.77x. Investors pay ₹362 for every ₹1 of annual earnings.
How is SOLARA performing according to Bull Run's analysis?
SOLARA has a Bull Run fundamental score of N/A/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SOLARA belong to?
SOLARA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Solara Active Pharma Sciences Ltd share price.
What is Return on Equity (ROE) and why is it important for SOLARA?
SOLARA has an ROE of 0.05%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Solara Active Pharma Sciences Ltd generates profits from shareholders capital.
How is SOLARA debt-to-equity ratio and what does it indicate?
SOLARA has a debt-to-equity ratio of 0.51, which indicates moderate leverage that should be monitored.
What is SOLARA dividend yield and is it a good dividend stock?
SOLARA offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Solara Active Pharma Sciences Ltd shares.
How has SOLARA share price grown over the past 5 years?
SOLARA has achieved 5-year growth rates of: Sales Growth -0.58%, Profit Growth -65.77%, and EPS Growth -65.82%.
What is the promoter holding in SOLARA and why does it matter?
Promoters hold 42.01% of SOLARA shares, with 35.32% pledged. High promoter holding often indicates strong management confidence in Solara Active Pharma Sciences Ltd.
What is SOLARA market capitalisation category?
SOLARA has a market capitalisation of ₹2317 crores, placing it in the Small-cap category.
How volatile is SOLARA stock?
SOLARA has a beta of N/A. A beta > 1 suggests the Solara Active Pharma Sciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SOLARA operating profit margin trend?
SOLARA has a 5-year average Operating Profit Margin (OPM) of 10.32%, indicating the company's operational efficiency.
How is SOLARA quarterly performance?
Recent quarterly performance shows Solara Active Pharma Sciences Ltd YoY Sales Growth of -9.63% and YoY Profit Growth of -226.09%.
What is the institutional holding pattern in SOLARA?
SOLARA has FII holding of 13.58% and DII holding of 2.69%. Significant institutional holding often suggests professional confidence in the Solara Active Pharma Sciences Ltd stock.